AGÕæÈ˹ٷ½

STOCK TITAN

[S-8] Viridian Therapeutics, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

On 31 July 2025, RH’s wholly-owned subsidiary Restoration Hardware, Inc. executed a Second Amendment to its Twelfth Amended & Restated Credit Agreement with Bank of America and other lenders.

  • Maturity extended: Revolving credit facility now matures four years later than the prior agreement.
  • Total capacity: Up to $600 million revolver, with a $300 million accordion that can lift total borrowing to $900 million; accordion may be structured as first-in, last-out term debt.
  • Subsidiary sub-limits: $10 million for RH Canada and $100 million for RH Geneva. European subsidiaries may access a separate sub-facility subject to conditions.
  • Covenants: No regular leverage covenants; a 1.0x fixed-charge coverage ratio applies only when unused availability falls below the greater of $40 million or 10 % of borrowing availability.
  • Collateral: Facility remains asset-based and secured by inventory, receivables and certain IP.

All other affirmative and negative covenants, reporting requirements and collateral arrangements remain largely unchanged. Item 2.03 confirms the amendment constitutes a direct financial obligation. Exhibit 10.1 contains the full text of the amendment.

Il 31 luglio 2025, la controllata interamente posseduta di RH, Restoration Hardware, Inc., ha eseguito un Secondo Emendamento al suo Dodicesimo Accordo di Credito Emendato e Ristabilito con Bank of America e altri finanziatori.

  • Scadenza estesa: La linea di credito revolving scade ora quattro anni dopo rispetto al precedente accordo.
  • Capacità totale: Fino a 600 milioni di dollari di revolving, con un accordeon da 300 milioni di dollari che può portare il totale del prestito a 900 milioni di dollari; l'accordeon può essere strutturato come debito a termine first-in, last-out.
  • Sub-limiti per le controllate: 10 milioni di dollari per RH Canada e 100 milioni di dollari per RH Ginevra. Le controllate europee possono accedere a una sub-linea separata soggetta a condizioni.
  • Convenzioni: Nessuna convenzione regolare sul leverage; un rapporto di copertura delle spese fisse di 1,0x si applica solo quando la disponibilità inutilizzata scende al di sotto del maggiore tra 40 milioni di dollari o il 10% della disponibilità di prestito.
  • Garanzie: La linea rimane basata su asset ed è garantita da inventario, crediti e alcune proprietà intellettuali.

Tutte le altre convenzioni positive e negative, i requisiti di rendicontazione e gli accordi sulle garanzie rimangono sostanzialmente invariati. L'Elemento 2.03 conferma che l'emendamento costituisce un obbligo finanziario diretto. L'Esibizione 10.1 contiene il testo completo dell'emendamento.

El 31 de julio de 2025, la subsidiaria de propiedad total de RH, Restoration Hardware, Inc., ejecutó una Segunda Enmienda a su Duodécimo Acuerdo de Crédito Enmendado y Restablecido con Bank of America y otros prestamistas.

  • Plazo extendido: La línea de crédito revolvente ahora vence cuatro años después que el acuerdo anterior.
  • Capacidad total: Hasta 600 millones de dólares en revolvente, con un acordeón de 300 millones de dólares que puede aumentar el total de préstamos a 900 millones de dólares; el acordeón puede estructurarse como deuda a plazo first-in, last-out.
  • Sublímites para subsidiarias: 10 millones de dólares para RH Canadá y 100 millones de dólares para RH Ginebra. Las subsidiarias europeas pueden acceder a una sublínea separada sujeta a condiciones.
  • Convenios: No hay convenios regulares de apalancamiento; un ratio de cobertura de cargos fijos de 1.0x se aplica solo cuando la disponibilidad no utilizada cae por debajo del mayor entre 40 millones de dólares o el 10% de la disponibilidad de préstamo.
  • ³Ò²¹°ù²¹²Ô³Ùí²¹²õ: La línea sigue siendo basada en activos y está garantizada por inventarios, cuentas por cobrar y ciertos activos de propiedad intelectual.

Todos los demás convenios positivos y negativos, requisitos de reporte y acuerdos de garantía permanecen en gran medida sin cambios. El ítem 2.03 confirma que la enmienda constituye una obligación financiera directa. El Anexo 10.1 contiene el texto completo de la enmienda.

2025ë…� 7ì›� 31ì�, RHì� ì „ì•¡ ì¶œìž ìžíšŒì‚¬ì¸ Restoration Hardware, Inc.ëŠ� Bank of America ë°� 기타 대출기관ê³� ì²´ê²°í•� ì �12ì°� 수정 ë°� 재작ì„� ì‹ ìš© 계약ì—� 대í•� ë‘� 번째 수정ì•�ì� 실행했습니다.

  • 만기 연장: 회전 ì‹ ìš© 한ë„ëŠ� ì´ì „ 계약보다 4ë…� ë� 연장ë˜ì—ˆìŠµë‹ˆë‹�.
  • ì´� 한ë„: 최대 6ì–� 달러ì� 회전 ì‹ ìš©, 추가ë¡� 3ì–� 달러 어코디언ì� 통해 ì´� 대ì¶� 한ë„ë¥� 9ì–� 달러까지 늘릴 ìˆ� 있으ë©�, ì–´ì½”ë””ì–¸ì€ ì„ ìž…ì„ ì¶œ(term debt first-in, last-out) ë°©ì‹ìœ¼ë¡œ êµ¬ì¡°í™”ë  ìˆ� 있습니다.
  • ìžíšŒì‚� 하위 한ë„: RH ìºë‚˜ë‹¤ì— 1,000ë§� 달러, RH ì œë„¤ë°”ì— 1ì–� 달러가 ë°°ì •ë˜ì—ˆìŠµë‹ˆë‹�. 유럽 ìžíšŒì‚¬ë“¤ì€ ì¡°ê±´ì—� ë”°ë¼ ë³„ë„ì� 하위 시설ì� ì´ìš©í•� ìˆ� 있습니다.
  • 약정: 정기ì ì¸ 레버리지 ì•½ì •ì€ ì—†ìœ¼ë©�, 미사ìš� 가능액ì� 4,000ë§� 달러 ë˜ëŠ” 대ì¶� 가능액ì� 10% ì¤� í� 금액 아래ë¡� 떨어ì§� 때만 1.0ë°� 고정비용 커버리지 비율ì� ì ìš©ë©ë‹ˆë‹�.
  • ë‹´ë³´: ì� ì‹œì„¤ì€ ìžì‚° 기반ì´ë©° 재고, 매출채권 ë°� 특정 ì§€ì � 재산권으ë¡� ë‹´ë³´ë©ë‹ˆë‹�.

기타 모든 ê¸ì •ì � ë°� ë¶€ì •ì  ì•½ì •, ë³´ê³  요구사항 ë°� ë‹´ë³´ ì¡°ê±´ì€ ëŒ€ë¶€ë¶� 변경ë˜ì§€ 않았습니ë‹�. 항목 2.03ì€ ì� ìˆ˜ì •ì•ˆì´ ì§ì ‘ì ì¸ 금융 ì˜ë¬´ìž„ì„ í™•ì¸í•©ë‹ˆë‹�. ë¶€ë¡� 10.1ì—는 수정ì•� ì „ì²´ í…스트가 í¬í•¨ë˜ì–´ 있습니다.

Le 31 juillet 2025, la filiale détenue à 100 % par RH, Restoration Hardware, Inc., a exécuté un Deuxième Amendement à son Douzième Accord de Crédit Modifié et Révisé avec Bank of America et d'autres prêteurs.

  • Échéance prolongée : La facilité de crédit renouvelable arrive désormais à échéance quatre ans plus tard que dans l'accord précédent.
  • Capacité totale : ´³³Ü²õ±ç³Ü'à 600 millions de dollars de crédit renouvelable, avec un accordéon de 300 millions de dollars pouvant porter l'emprunt total à 900 millions de dollars ; l'accordéon peut être structuré en dette à terme first-in, last-out.
  • Sous-limites pour les filiales : 10 millions de dollars pour RH Canada et 100 millions de dollars pour RH Genève. Les filiales européennes peuvent accéder à une sous-facilité distincte sous conditions.
  • Covenants : Pas de covenants d'endettement réguliers ; un ratio de couverture des charges fixes de 1,0x s'applique uniquement lorsque la disponibilité inutilisée tombe en dessous du plus élevé entre 40 millions de dollars ou 10 % de la disponibilité d'emprunt.
  • Garanties : La facilité reste basée sur les actifs et est garantie par les stocks, les créances et certains droits de propriété intellectuelle.

Tous les autres covenants positifs et négatifs, les exigences de reporting et les arrangements de garanties restent largement inchangés. L'article 2.03 confirme que l'amendement constitue une obligation financière directe. L'Exhibit 10.1 contient le texte complet de l'amendement.

Am 31. Juli 2025 hat die hundertprozentige Tochtergesellschaft von RH, Restoration Hardware, Inc., eine Zweite Änderung ihres Zwölften geänderten und neu gefassten Kreditvertrags mit der Bank of America und weiteren Kreditgebern ausgeführt.

  • Fälligkeit verlängert: Die revolvierende Kreditfazilität läuft nun vier Jahre länger als im vorherigen Vertrag.
  • ³Ò±ð²õ²¹³¾³Ù°ì²¹±è²¹³ú¾±³Ùä³Ù: Bis zu 600 Millionen US-Dollar Revolving-Kredit mit einer 300 Millionen US-Dollar Akkordeon-Option, die die Gesamtaufnahme auf 900 Millionen US-Dollar erhöhen kann; das Akkordeon kann als First-in, Last-out-Termindarlehen strukturiert werden.
  • Untergrenzen für Tochtergesellschaften: 10 Millionen US-Dollar für RH Kanada und 100 Millionen US-Dollar für RH Genf. Europäische Tochtergesellschaften können unter bestimmten Bedingungen auf eine separate Unterfazilität zugreifen.
  • Klauseln: Keine regulären Verschuldungsklauseln; eine 1,0-fache Deckungsquote für Fixkosten gilt nur, wenn die ungenutzte Verfügbarkeit unter den höheren Wert von 40 Millionen US-Dollar oder 10 % der Kreditverfügbarkeit fällt.
  • Sicherheiten: Die Fazilität bleibt asset-basiert und ist durch Inventar, Forderungen und bestimmte geistige Eigentumsrechte besichert.

Alle anderen positiven und negativen Klauseln, Berichtspflichten und Sicherheitenvereinbarungen bleiben weitgehend unverändert. Punkt 2.03 bestätigt, dass die Änderung eine direkte finanzielle Verpflichtung darstellt. Anlage 10.1 enthält den vollständigen Text der Änderung.

Positive
  • Maturity extended by four years, reducing near-term refinancing risk.
  • Accordion feature up to $300 million offers optional incremental liquidity.
  • No regular leverage covenants; FCCR springs only under low-availability conditions.
Negative
  • Facility remains fully secured, further encumbering assets.
  • Restrictive negative covenants limit dividends, additional debt, and asset sales.

Insights

TL;DR: Maturity extension preserves liquidity; asset-based structure and modest FCCR trigger limit covenant risk.

Extending the revolver by four years materially de-risks near-term refinancing for RH, keeping a sizable $600 m facility in place—with potential to reach $900 m via the accordion. Because the FCCR covenant springs only when availability dips below $40 m or 10 % of the base, covenant default risk is low as long as inventory and receivables remain healthy. The secured nature protects lenders but restricts RH’s asset flexibility and dividend capacity. Overall, a neutral-to-positive credit event: improved tenor outweighs additional encumbrance already present.

TL;DR: Longer liquidity runway supports strategic investments; covenant structure caps downside but limits shareholder distributions.

For shareholders, the four-year push-out removes a refinancing overhang and ensures access to working-capital funding as RH executes its international gallery rollout. The absence of leverage covenants provides operational flexibility during macro softness. However, the asset pledge and dividend restrictions may constrain capital returns. With no change to borrowing capacity, the amendment is not revenue-accretive but reduces tail risk—mildly positive for valuation multiples.

Il 31 luglio 2025, la controllata interamente posseduta di RH, Restoration Hardware, Inc., ha eseguito un Secondo Emendamento al suo Dodicesimo Accordo di Credito Emendato e Ristabilito con Bank of America e altri finanziatori.

  • Scadenza estesa: La linea di credito revolving scade ora quattro anni dopo rispetto al precedente accordo.
  • Capacità totale: Fino a 600 milioni di dollari di revolving, con un accordeon da 300 milioni di dollari che può portare il totale del prestito a 900 milioni di dollari; l'accordeon può essere strutturato come debito a termine first-in, last-out.
  • Sub-limiti per le controllate: 10 milioni di dollari per RH Canada e 100 milioni di dollari per RH Ginevra. Le controllate europee possono accedere a una sub-linea separata soggetta a condizioni.
  • Convenzioni: Nessuna convenzione regolare sul leverage; un rapporto di copertura delle spese fisse di 1,0x si applica solo quando la disponibilità inutilizzata scende al di sotto del maggiore tra 40 milioni di dollari o il 10% della disponibilità di prestito.
  • Garanzie: La linea rimane basata su asset ed è garantita da inventario, crediti e alcune proprietà intellettuali.

Tutte le altre convenzioni positive e negative, i requisiti di rendicontazione e gli accordi sulle garanzie rimangono sostanzialmente invariati. L'Elemento 2.03 conferma che l'emendamento costituisce un obbligo finanziario diretto. L'Esibizione 10.1 contiene il testo completo dell'emendamento.

El 31 de julio de 2025, la subsidiaria de propiedad total de RH, Restoration Hardware, Inc., ejecutó una Segunda Enmienda a su Duodécimo Acuerdo de Crédito Enmendado y Restablecido con Bank of America y otros prestamistas.

  • Plazo extendido: La línea de crédito revolvente ahora vence cuatro años después que el acuerdo anterior.
  • Capacidad total: Hasta 600 millones de dólares en revolvente, con un acordeón de 300 millones de dólares que puede aumentar el total de préstamos a 900 millones de dólares; el acordeón puede estructurarse como deuda a plazo first-in, last-out.
  • Sublímites para subsidiarias: 10 millones de dólares para RH Canadá y 100 millones de dólares para RH Ginebra. Las subsidiarias europeas pueden acceder a una sublínea separada sujeta a condiciones.
  • Convenios: No hay convenios regulares de apalancamiento; un ratio de cobertura de cargos fijos de 1.0x se aplica solo cuando la disponibilidad no utilizada cae por debajo del mayor entre 40 millones de dólares o el 10% de la disponibilidad de préstamo.
  • ³Ò²¹°ù²¹²Ô³Ùí²¹²õ: La línea sigue siendo basada en activos y está garantizada por inventarios, cuentas por cobrar y ciertos activos de propiedad intelectual.

Todos los demás convenios positivos y negativos, requisitos de reporte y acuerdos de garantía permanecen en gran medida sin cambios. El ítem 2.03 confirma que la enmienda constituye una obligación financiera directa. El Anexo 10.1 contiene el texto completo de la enmienda.

2025ë…� 7ì›� 31ì�, RHì� ì „ì•¡ ì¶œìž ìžíšŒì‚¬ì¸ Restoration Hardware, Inc.ëŠ� Bank of America ë°� 기타 대출기관ê³� ì²´ê²°í•� ì �12ì°� 수정 ë°� 재작ì„� ì‹ ìš© 계약ì—� 대í•� ë‘� 번째 수정ì•�ì� 실행했습니다.

  • 만기 연장: 회전 ì‹ ìš© 한ë„ëŠ� ì´ì „ 계약보다 4ë…� ë� 연장ë˜ì—ˆìŠµë‹ˆë‹�.
  • ì´� 한ë„: 최대 6ì–� 달러ì� 회전 ì‹ ìš©, 추가ë¡� 3ì–� 달러 어코디언ì� 통해 ì´� 대ì¶� 한ë„ë¥� 9ì–� 달러까지 늘릴 ìˆ� 있으ë©�, ì–´ì½”ë””ì–¸ì€ ì„ ìž…ì„ ì¶œ(term debt first-in, last-out) ë°©ì‹ìœ¼ë¡œ êµ¬ì¡°í™”ë  ìˆ� 있습니다.
  • ìžíšŒì‚� 하위 한ë„: RH ìºë‚˜ë‹¤ì— 1,000ë§� 달러, RH ì œë„¤ë°”ì— 1ì–� 달러가 ë°°ì •ë˜ì—ˆìŠµë‹ˆë‹�. 유럽 ìžíšŒì‚¬ë“¤ì€ ì¡°ê±´ì—� ë”°ë¼ ë³„ë„ì� 하위 시설ì� ì´ìš©í•� ìˆ� 있습니다.
  • 약정: 정기ì ì¸ 레버리지 ì•½ì •ì€ ì—†ìœ¼ë©�, 미사ìš� 가능액ì� 4,000ë§� 달러 ë˜ëŠ” 대ì¶� 가능액ì� 10% ì¤� í� 금액 아래ë¡� 떨어ì§� 때만 1.0ë°� 고정비용 커버리지 비율ì� ì ìš©ë©ë‹ˆë‹�.
  • ë‹´ë³´: ì� ì‹œì„¤ì€ ìžì‚° 기반ì´ë©° 재고, 매출채권 ë°� 특정 ì§€ì � 재산권으ë¡� ë‹´ë³´ë©ë‹ˆë‹�.

기타 모든 ê¸ì •ì � ë°� ë¶€ì •ì  ì•½ì •, ë³´ê³  요구사항 ë°� ë‹´ë³´ ì¡°ê±´ì€ ëŒ€ë¶€ë¶� 변경ë˜ì§€ 않았습니ë‹�. 항목 2.03ì€ ì� ìˆ˜ì •ì•ˆì´ ì§ì ‘ì ì¸ 금융 ì˜ë¬´ìž„ì„ í™•ì¸í•©ë‹ˆë‹�. ë¶€ë¡� 10.1ì—는 수정ì•� ì „ì²´ í…스트가 í¬í•¨ë˜ì–´ 있습니다.

Le 31 juillet 2025, la filiale détenue à 100 % par RH, Restoration Hardware, Inc., a exécuté un Deuxième Amendement à son Douzième Accord de Crédit Modifié et Révisé avec Bank of America et d'autres prêteurs.

  • Échéance prolongée : La facilité de crédit renouvelable arrive désormais à échéance quatre ans plus tard que dans l'accord précédent.
  • Capacité totale : ´³³Ü²õ±ç³Ü'à 600 millions de dollars de crédit renouvelable, avec un accordéon de 300 millions de dollars pouvant porter l'emprunt total à 900 millions de dollars ; l'accordéon peut être structuré en dette à terme first-in, last-out.
  • Sous-limites pour les filiales : 10 millions de dollars pour RH Canada et 100 millions de dollars pour RH Genève. Les filiales européennes peuvent accéder à une sous-facilité distincte sous conditions.
  • Covenants : Pas de covenants d'endettement réguliers ; un ratio de couverture des charges fixes de 1,0x s'applique uniquement lorsque la disponibilité inutilisée tombe en dessous du plus élevé entre 40 millions de dollars ou 10 % de la disponibilité d'emprunt.
  • Garanties : La facilité reste basée sur les actifs et est garantie par les stocks, les créances et certains droits de propriété intellectuelle.

Tous les autres covenants positifs et négatifs, les exigences de reporting et les arrangements de garanties restent largement inchangés. L'article 2.03 confirme que l'amendement constitue une obligation financière directe. L'Exhibit 10.1 contient le texte complet de l'amendement.

Am 31. Juli 2025 hat die hundertprozentige Tochtergesellschaft von RH, Restoration Hardware, Inc., eine Zweite Änderung ihres Zwölften geänderten und neu gefassten Kreditvertrags mit der Bank of America und weiteren Kreditgebern ausgeführt.

  • Fälligkeit verlängert: Die revolvierende Kreditfazilität läuft nun vier Jahre länger als im vorherigen Vertrag.
  • ³Ò±ð²õ²¹³¾³Ù°ì²¹±è²¹³ú¾±³Ùä³Ù: Bis zu 600 Millionen US-Dollar Revolving-Kredit mit einer 300 Millionen US-Dollar Akkordeon-Option, die die Gesamtaufnahme auf 900 Millionen US-Dollar erhöhen kann; das Akkordeon kann als First-in, Last-out-Termindarlehen strukturiert werden.
  • Untergrenzen für Tochtergesellschaften: 10 Millionen US-Dollar für RH Kanada und 100 Millionen US-Dollar für RH Genf. Europäische Tochtergesellschaften können unter bestimmten Bedingungen auf eine separate Unterfazilität zugreifen.
  • Klauseln: Keine regulären Verschuldungsklauseln; eine 1,0-fache Deckungsquote für Fixkosten gilt nur, wenn die ungenutzte Verfügbarkeit unter den höheren Wert von 40 Millionen US-Dollar oder 10 % der Kreditverfügbarkeit fällt.
  • Sicherheiten: Die Fazilität bleibt asset-basiert und ist durch Inventar, Forderungen und bestimmte geistige Eigentumsrechte besichert.

Alle anderen positiven und negativen Klauseln, Berichtspflichten und Sicherheitenvereinbarungen bleiben weitgehend unverändert. Punkt 2.03 bestätigt, dass die Änderung eine direkte finanzielle Verpflichtung darstellt. Anlage 10.1 enthält den vollständigen Text der Änderung.

As filed with the Securities and Exchange Commission on August 6, 2025

Registration No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

VIRIDIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   47-1187261

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

Viridian Therapeutics, Inc.

221 Crescent Street, Suite 103A

Waltham, MA 02453

(Address of Principal Executive Offices, Zip Code)

Viridian Therapeutics, Inc. Amended & Restated 2016 Equity Incentive Plan

Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan

Viridian Therapeutics, Inc. Stock Option Inducement Awards

(Full title of the plans)

Jennifer Tousignant

Chief Legal Officer

221 Crescent Street, Suite 103A

Waltham, MA 02453

(617) 272-4600

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to: 

Zachary R. Blume

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199

(617) 951-7000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

Viridian Therapeutics, Inc., a Delaware corporation (the “Registrant”), is filing this Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. The Registrant increased the number of shares of its common stock, par value $0.01 per share (“Common Stock”), available for issuance under its Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”) by 8,000,000 shares.

Additionally, the Registrant is registering (i) 2,000,000 shares of the Registrant’s Common Stock under the Registrant’s 2025 Employee Stock Purchase Plan (the “2025 ESPP”), and (ii) 1,228,650 additional shares of Common Stock subject to stock options granted to certain employees (the “Inducement Grants”). The Inducement Grants have been granted outside of the Company’s Amended and Restated 2016 Plan but remain subject to the terms and conditions of such 2016 Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with the Registrant in accordance with Nasdaq Listing Rule 5635(c)(4). Such Inducement Grants are unvested and unexercisable as of the date of this Registration Statement.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

Item 1.

Plan Information

Documents containing the information specified in Part I of Form S-8 have been and/or will be sent or given to participants of the 2016 Plan and the 2025 ESPP and recipients of the Inducement Grants as specified by Rule 428(b)(1) of the Securities Act. In accordance with the instructions of Part I of Form S-8, such documents will not be filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus as required by Section 10(a) of the Securities Act.

 

Item 2.

Registrant Information and Employee Plan Annual Information

Not required to be filed with this registration statement.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3.

Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission are incorporated by reference herein and shall be deemed to be a part hereof:

 

   

the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 3, 2025;


   

the Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2025, filed on May 6, 2025 and for the fiscal quarter ended on June  30, 2025, filed on August 6, 2025;

 

   

the Current Reports on Form 8-K filed with the Commission on January 10, 2025, March  4, 2025, March  10, 2025, April  7, 2025, June  24, 2025, and July 30, 2025;

 

   

The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No.  001-36483) filed with the Commission on June 6, 2014, pursuant to Rule 12g-3 promulgated under the Exchange Act, as updated by Exhibit 4.5 to the Annual Report on Form 10-K for the fiscal year ended December  31, 2023, filed on February 27, 2024, including any amendment or report filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities being offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part hereof from the dates of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

Any statement contained in a document incorporated, or deemed to be incorporated, by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 4.

Description of Securities.

Not applicable.

 

Item 5.

Interests of Named Experts and Counsel.

Not applicable.

 

Item 6.

Indemnification of Directors and Officers.

The Registrant is a Delaware corporation. Section 145(a) of the Delaware General Corporation Law, or the DGCL, provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.


Further subsections of DGCL Section 145 provide that:

(1) to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys’ fees, actually and reasonably incurred by such person in connection therewith;

(2) the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

(3) the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145.

As used in this Item 6, the term “proceeding” means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the company, and whether civil, criminal, administrative, investigative or otherwise.

Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Registrant under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. Provisions in the company’s certificate of incorporation and amended and restated bylaws limit or eliminate the personal liability of the directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to the Registrant or the Registrant’s stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

 

   

any breach of the director’s duty of loyalty to the Registrant or the Registrant’s stockholders;

 

   

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

   

any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

 

   

any transaction from which the director derived an improper personal benefit.

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies, such as an injunction or rescission.

In addition, the Registrant’s bylaws provide that:

 

   

the Registrant will indemnify its directors, officers and, in the discretion of the Registrant’s board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

 

   

the Registrant will advance reasonable expenses, including attorneys’ fees, to directors and, in the discretion of the board of directors, to officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the Registrant, subject to limited exceptions.


The Registrant has entered into indemnification agreements with each of the directors and executive officers. These agreements provide that the Registrant will indemnify each of the Registrant’s directors, executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. The Registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and the Registrant will indemnify the directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Registrant or in furtherance of its rights. Additionally, certain of the directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, the Registrant has agreed in the indemnification agreements that the Registrant’s obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

The Registrant also maintains general liability insurance which covers certain liabilities of the directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

 

Item 7.

Exemption from Registration Claimed.

Not applicable.


Item 8.

  

Exhibits.

 

Exhibit No.

  

Exhibit Description

  4.1    Amended and Restated Certificate of Incorporation of the Registrant, effective as of March  9, 2022 (Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K filed on March 11, 2022 (File No. 001-36483)).
  4.2    Fourth Amended and Restated Bylaws of the Registrant, effective as of December  15, 2023 (Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 18, 2023 (File No. 001-36843)).
  5.1*    Opinion of Ropes & Gray LLP.
 23.1*    Consent of Ropes & Gray LLP (included in Exhibit 5.1).
 23.2*    Consent of KPMG LLP, independent registered public accounting firm.
 24.1*    Power of Attorney (included on signature page hereto).
 99.1    Registrant’s Amended  & Restated 2016 Equity Incentive Plan (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June  24, 2025 (File No. 001-36483)).
 99.2    Registrant’s 2025 Employee Stock Purchase Plan (Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed on August 6, 2025 (File No. 001-36483)).
 99.3    Form of Inducement Stock Option Agreement (Incorporated herein by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 filed on March 11, 2022 (File No. 333-263490)). 
107.1*    Filing Fee Table

 

*

Filed herewith.

 

Item 9.

Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and


(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement;

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Waltham, Commonwealth of Massachusetts, on August 6, 2025.

 

VIRIDIAN THERAPEUTICS, INC.
By:  

/s/ Stephen Mahoney

Name: Stephen Mahoney
Title: President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Stephen Mahoney and Seth Harmon, and each of them severally, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution for him or her and in his or her name, place, and stead in any and all capacities to sign any and all amendments (including post-effective amendments and amendments filed pursuant to Rule 462(b) under the Securities Act of 1933) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or of his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

  

Title

  

Date

/s/ Stephen Mahoney

  

President, Chief Executive Officer and Director

  

August 6, 2025

Stephen Mahoney   

(Principal Executive Officer)

  

/s/ Seth Harmon

  

Chief Financial Officer

  

August 6, 2025

Seth Harmon    (Principal Financial Officer; Principal Accounting Officer)   

/s/ Tomas Kiselak

  

Chairman of the Board

  

August 6, 2025

Tomas Kiselak      

/s/ Jeff Ajer

  

Director

  

August 6, 2025

Jeff Ajer      

/s/ Chris Cain

  

Director

  

August 6, 2025

Chris Cain, Ph.D.      

/s/ Sarah Gheuens

  

Director

  

August 6, 2025

Sarah Gheuens, M.D., Ph.D.      

/s/ Arlene Morris

  

Director

  

August 6, 2025

Arlene Morris      

/s/ Jennifer Moses

  

Director

  

August 6, 2025

Jennifer Moses      

FAQ

How much liquidity does the amended RH credit facility provide?

The revolver allows up to $600 million, expandable to $900 million via a $300 million accordion.

What is the new maturity date of RH’s revolving credit facility?

The amendment extends the maturity by four additional years from the prior July 2021 agreement.

Are there financial covenants in RH’s amended credit agreement?

Only a 1.0× fixed-charge coverage ratio applies when unused availability falls below specified thresholds; no ongoing leverage tests.

Which RH subsidiaries have dedicated sub-limits?

$10 million is reserved for Restoration Hardware Canada and $100 million for RH Geneva; European subsidiaries may obtain a separate facility.

What collateral secures RH’s credit facility?

Substantial assets including inventory, receivables and certain intellectual property secure all obligations.
Viridian Therapeutics Inc

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Latest SEC Filings

VRDN Stock Data

1.42B
80.80M
0.16%
114.78%
14.27%
Biotechnology
Services-medical Laboratories
United States
WALTHAM